Clinical trials: Cerebral Small Vessels Disease
Cerebral Small Vessel Diseases, MRI
Magnetic Resonance Imaging in Cerebral Small Vessel Disease
Cerebral small vessel disease (cSVD) accounts for 20% of ischemic strokes and is the most common cause of vascular cognitive impairment.
- Trial name
- NCT05200377
- Testing
- Magnetic resonance imaging
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
The purpose of this study is to determine the safety and efficacy of a therapeutic regimen consisting of 4 weeks of glucocorticoids given with a combination of the usual induction agents for ANCA-associated vasculitis.
- Trial name
- SAFE-LOW (NCT06983821)
- Testing
- Cyclophosphamide, Standard of Care (SOC), Prednisone
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Hospital Research Institute
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Angiokeratomas, Chronic Kidney Disease
Biomarker for Patients With Fabry Disease (BioFabry)
Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood
- Conditions
- Angiokeratomas, Chronic Kidney Disease, Ocular Abnormalities, Hearing Loss
- Trial name
- BioFabry (NCT02778295)
- Where
- 3 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis.
- Trial name
- RAVELOS (NCT01586858)
- Testing
- Observational
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 67 people
- Sponsor
- Johns Hopkins University
Fabry Disease
Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta
This study is a prospective active comparator study to assess the immune response elicited by human recombinant agalsidase therapy in subjects who are switching from agalsidase alfa to agalsidase beta with Fabry disease.
- Trial name
- NCT01745185
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- O & O Alpan LLC
Cerebral Small Vessel Diseases
Recovery Improved in Covert Stroke With Exercise
Silent ischemic, also known as "covert stroke vascular disease" (CSVD), contributes to neurological deficits that are caused by damage to small blood vessels in the brain.
- Trial name
- RISE-2 (NCT02068391)
- Testing
- Stretching Program, Exercise Program
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Fabry Disease
FASHION Fabry Disease Hypertrophic Cardiomyopathy and Infammation
In Fabry disease (FD) and hypertrophic cardiomyopathy (HCM) systemic inflammation recently gained attention as a possible key pathophysiologic process involved in the development of cardiac hypertrophy and progression of the…
- Trial name
- FASHION (NCT05761834)
- Testing
- Sample blood and 2D-echocardiography with Doppler
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fabry Disease
A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.
- Trial name
- NCT00214500
- Testing
- migalastat HCl
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Amicus Therapeutics
Fabry Disease, Alpha Galactosidase A Deficiency
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
The study was planned for up to 2 years (24 months). Planned full participation for both mother and infant was 24 months, planned full participation of mother and development of infant was 24 months, while planned full…
- Trial name
- NCT00230607
- Testing
- agalsidase beta
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 7 people
- Sponsor
- Genzyme, a Sanofi Company
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Fabry Disease
A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00312767
- Testing
- Fabrazyme (agalsidase beta)
- Where
- United States
- Sponsor
- Genzyme, a Sanofi Company
Fabry Disease
A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.
The purpose of this survey is to identify any concerns regarding the following efficacy and safety-related issues in clinical practice with the new drugs "Fabrazyme for intravenous infusion 5mg" and "Fabrazyme for intravenous…
- Trial name
- NCT00233870
- Testing
- Agalsidase beta (recombinant form)
- Where
- Japan
- Volunteers
- 405 people
- Sponsor
- Genzyme, a Sanofi Company
Cerebral Small Vessel Diseases
Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients
A. the controlling of the blood pressure, especially the variation of blood pressure, can slow down the development of the small vessel disease.
- Trial name
- APPROVE (NCT01819441)
- Testing
- Azelnidipine, Perindopril, hydrochlorothiazide
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Yining Huang
Fabry Disease
Natural History in Fabry Disease With IVS4+919G>A Mutations
Fabry disease (FD) is a genetic condition where mutations in the GLA gene cause low activity of an important enzyme (alpha-Galactosidase A). This leads to harmful substances building up in the body.
- Trial name
- NCT07506083
- Where
- Hong Kong
- Volunteers
- 31 people
- Sponsor
- Chinese University of Hong Kong
ANCA Associated Vasculitis, Microscopic Polyangiitis
Hydroxychloroquine in ANCA Vasculitis Evaluation
The purpose of this study is to find out whether hydroxychloroquine, in addition to background treatments, reduces disease activity in patients with Anti-Neutrophilic Cytoplasmic Autoantibodies (ANCA) Vasculitis, a group of…
- Conditions
- ANCA Associated Vasculitis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Wegener Granulomatosis
- Trial name
- HAVEN (NCT04316494)
- Testing
- Hydroxychloroquine
- Where
- 18 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
MELAS Syndrome, Mitochondrial Diseases
Ketones & Mitochondrial Heteroplasmy
The current study is a prospective evaluation of the ability of ketosis to shift mitochondrial DNA (mtDNA) heteroplasmy in subjects harboring a known mutation in their mtDNA at position 3243 (A>G).
- Trial name
- NCT01252979
- Testing
- Medium-Chain Triglycerides
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- The University of Texas Health Science Center, Houston
Fabry Disease
Anderson Fabry Disease - the Power of Information.
The goal of this before-after control-impact study is to determine whether providing targeted information on Fabry disease (FD) to cardiologists and tutoring them in the evaluation of patients with unexplained left ventricle…
- Trial name
- NCT07136662
- Testing
- educational
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pulmonary Fibrosis
Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
The purpose of this study is to determine wether pirfenidone is safe and effective in the treatment of pulmonary fibrosis with anti-myeloperoxydase (MPO) antibodies or pulmonary fibrosis with anti-MPO associated vasculitis.
- Trial name
- PIRFENIVAS (NCT03385668)
- Testing
- Pirfenidone
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Giant Cell Arteritis, Takayasu's Arteritis
Reproductive Health in Men and Women With Vasculitis
The purpose of this study is to learn about reproductive health, including fertility and pregnancies, in people with vasculitis.
- Conditions
- Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis
- Trial name
- NCT02176070
- Where
- United States
- Volunteers
- 467 people
- Sponsor
- University of South Florida